The Renin–Angiotensin System in COVID-19: Can Long COVID Be Predicted?
Abstract
:1. Introduction
1.1. The Renin–Angiotensin System and COVID-19
1.2. Dysregulated Serum ACE and CPN Activity in Convalescent COVID-19 Patients
2. Review and Discussion
2.1. The RAS
2.2. Antihypertensive Drugs ACEI/ARB and COVID-19
2.3. Long COVID
2.4. Is Reduced BK Serum Degradation in Convalescent Patients Indicative of Long COVID?
3. Conclusions
4. Reference Information
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Angeli, F.; Zappa, M.; Reboldi, G.; Gentile, G.; Trapasso, M.; Spanevello, A.; Verdecchia, P. The spike effect of acute respiratory syndrome coronavirus 2 and coronavirus disease 2019 vaccines on blood pressure. Eur. J. Intern. Med. 2023, 109, 12–21. [Google Scholar] [CrossRef] [PubMed]
- Paz Ocaranza, M.; Riquelme, J.A.; García, L.; Jalil, J.E.; Chiong, M.; Santos, R.A.S.; Lavandero, S. Counter-regulatory renin-angiotensin system in cardiovascular disease. Nat. Rev. Cardiol. 2020, 17, 116–129. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, H.; Peng, J.; Wang, T.; Wen, J.; Chen, S.; Huang, Y.; Zhang, Y. Counter-regulatory renin-angiotensin system in hypertension: Review and update in the era of COVID-19 pandemic. Biochem. Pharmacol. 2023, 208, 115370. [Google Scholar] [CrossRef]
- Bayer, M.; König, S. A vote for robustness: Monitoring serum enzyme activity by thin-layer chromatography of dabsylated bradykinin products. J. Pharmaceut. Biomed. Anal. 2017, 143, 199–203. [Google Scholar] [CrossRef]
- Tepasse, P.-R.; Vollenberg, R.; Steinebrey, N.; König, S. High angiotensin-converting enzyme and low carboxypeptidase N serum activity correlate with disease severity in COVID-19 patients. J. Pers. Med. 2022, 12, 406. [Google Scholar] [CrossRef]
- Tepasse, P.-R.; Vollenberg, R.; Steinebrey, N.; König, S. The dysregulation of the renin-angiotensin-system in COVID-19 studied by serum proteomics: Angiotensinogen increases with disease severity. Molecules 2022, 27, 2495. [Google Scholar] [CrossRef] [PubMed]
- Tabassum, A.; Iqbal, M.S.; Sultan, S.; Alhuthali, R.A.; Alshubaili, D.I.; Sayyam, R.S.; Abyad, L.M.; Qasem, A.H.; Arbaeen, A.F. Dysregulated bradykinin: Mystery in the pathogenesis of COVID-19. Mediat. Inflamm. 2022, 2022, 7423537. [Google Scholar] [CrossRef]
- Carvalho, P.R.; Sirois, P.; Fernandes, P.D. The role of kallikrein-kinin and renin-angiotensin systems in COVID-19 infection. Peptides 2021, 135, 170428. [Google Scholar] [CrossRef]
- Lawal, I.O.; Kgatle, M.M.; Mokoala, K.; Farate, A.; Sathekge, M.M. Cardiovascular disturbances in COVID-19: An updated review of the pathophysiology and clinical evidence of cardiovascular damage induced by SARS-CoV-2. BMC Cardiovasc. Disord. 2022, 22, 93. [Google Scholar] [CrossRef]
- Schieffer, E.; Schieffer, B. The race for ACE: Targeting angiotensin-converting enzymes (ACE) in SARS-CoV-2 infection. J. Renin-Angiotensin-Aldosterone Syst. JRAAS 2022, 2022, 2549063. [Google Scholar] [CrossRef]
- Matthews, K.W.; Mueller-Ortiz, S.L.; Wetsel, R.A. Carboxypeptidase N: A pleiotropic regulator of inflammation. Mol. Immunol. 2004, 40, 785–793. [Google Scholar] [CrossRef] [PubMed]
- Hrenak, J.; Paulis, L.; Simko, F. Angiotensin A/alamandine/MrgD axis: Another clue to understanding cardiovascular pathophysiology. Int. J. Mol. Sci. 2016, 17, 1098. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lucena, J.F.; Alegre, F.; Martinez-Urbistondo, D.; Landecho, M.F.; Huerta, A.; Garcia-Mouriz, A.; Garcia, N.; Quiroga, J. Performance of SAPS II and SAPS 3 in intermediate care. PLoS ONE 2013, 8, e77229. [Google Scholar] [CrossRef] [PubMed]
- Galbraith, M.D.; Kinning, K.T.; Sullivan, K.D.; Baxter, R.; Araya, P.; Jordan, K.R.; Russell, S.; Smith, K.P.; Granrath, R.E.; Shaw, J.; et al. Seroconversion stages COVID19 into distinct pathophysiological states. eLife 2021, 10, e65508. [Google Scholar] [CrossRef]
- Li, F.; Boon, A.C.M.; Michelson, A.P.; Foraker, R.E.; Zhan, M.; Payne, P.R.O. Estrogen hormone is an essential sex factor inhibiting inflammation and immune response in COVID-19. Sci. Rep. 2022, 12, 9462. [Google Scholar] [CrossRef]
- Davis, H.E.; McCorkell, L.; Vogel, J.M.; Topol, E.J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023, 21, 133–146. [Google Scholar] [CrossRef]
- Ning, Q.; Wu, D.; Wang, X.; Xi, D.; Chen, T.; Chen, G.; Wang, H.; Lu, H.; Wang, M.; Zhu, L.; et al. The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication. Signal Transduct. Target. Ther. 2022, 7, 57. [Google Scholar] [CrossRef]
- Armato, J.; DeFronzo, R.A.; Chiu, S.T.; Rider, D.; Ruby, R. Are angiotensin-converting enzyme inhibitors/angiotensin receptor blockers associated with reduced severe acute respiratory syndrome coronavirus 2 infections and improved outcomes, and does race matter? Diabetes Obes. Metab. 2022, 24, 2465–2468. [Google Scholar] [CrossRef]
- Kuba, K.; Imai, Y.; Rao, S.; Gao, H.; Guo, F.; Guan, B. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. 2005, 11, 875–879. [Google Scholar] [CrossRef]
- Arnold, R.G. COVID-19—Does this disease kill due to imbalance of the renin angiotensin system (RAS) caused by genetic and gender differences in the response to viral ACE2 attack? Heart Lung Circ. 2020, 29, 964–972. [Google Scholar] [CrossRef]
- Biswas, M.; Kali, M.S.K. Association of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers with risk of mortality, severity or SARS-CoV-2 test positivity in COVID-19 patients: Meta-analysis. Sci. Rep. 2021, 11, 5012. [Google Scholar] [CrossRef] [PubMed]
- Skarstein Kolberg, E. ACE2, COVID19 and serum ACE as a possible biomarker to predict severity of disease. J. Clin. Virol. 2020, 126, 104350. [Google Scholar] [CrossRef] [PubMed]
- Kai, H.; Kai, M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors—Lessons from available evidence and insights into COVID-19. Hypertens. Res. 2020, 43, 648–654. [Google Scholar] [CrossRef] [PubMed]
- Tsampasian, V.; Corballis, N.; Vassiliou, V.S. Renin-angiotensin-aldosterone inhibitors and COVID-19 infection. Curr. Hypertens. Rep. 2022, 24, 425–433. [Google Scholar] [CrossRef] [PubMed]
- Selçuk, M.; Çınar, T.; Keskin, M.; Çiçek, V.; Kılıç, Ş.; Kenan, B.; Doğan, S.; Asal, S.; Günay, N.; Yıldırım, E.; et al. Is the use of ACE inb/ARBs associated with higher in-hospital mortality in COVID-19 pneumonia patients? Clin. Exp. Hypertens. 2020, 42, 738–742. [Google Scholar] [CrossRef] [PubMed]
- Mehta, N.; Kalra, A.; Nowacki, A.S.; Anjewierden, S.; Han, Z.; Bhat, P.; Carmona-Rubio, A.E.; Jacob, M.; Procop, G.W.; Harrington, S.; et al. Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020, 5, 1020–1026. [Google Scholar] [CrossRef] [PubMed]
- Mehra, M.R.; Desai, S.S.; Kuy, S.R.; Henry, T.D.; Patel, A.N. Cardiovascular disease, drug therapy, and mortality in COVID-19. N. Engl. J. Med. 2020, 382, e102. [Google Scholar] [CrossRef]
- Duvvuri, V.R.; Baumgartner, A.; Molani, S.; Hernandez, P.V.; Yuan, D.; Roper, R.T.; Matos, W.F.; Robinson, M.; Su, Y.; Subramanian, N.; et al. Angiotensin-converting enzyme (ACE) inhibitors may moderate COVID-19 hyperinflammatory response: An observational study with deep immunophenotyping. Health Data Sci. 2022, 2022, 0002. [Google Scholar] [CrossRef]
- Sato, K.; White, N.; Fanning, J.P.; Obonyo, N.; Yamashita, M.H.; Appadurai, V.; Ciullo, A.; May, M.; Worku, E.T.; Helms, L.; et al. Impact of renin–angiotensin–aldosterone system inhibition on mortality in critically ill COVID-19 patients with pre-existing hypertension: A prospective cohort study. BMC Cardiovasc. Disord. 2022, 22, 123. [Google Scholar] [CrossRef]
- Huang, N.X.; Yuan, Q.; Fang, F.; Yan, B.P.; Sanderson, J.E. Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19. PLoS ONE 2023, 18, e0280280. [Google Scholar] [CrossRef]
- Loader, J.; Taylor, F.C.; Lampa, E.; Sundström, J. Renin-angiotensin aldosterone system inhibitors and COVID-19: A systematic review and meta-analysis revealing critical bias across a body of observational research. J. Am. Heart Assoc. 2022, 11, e025289. [Google Scholar] [CrossRef] [PubMed]
- Trump, S.; Lukassen, S.; Anker, M.S.; Chua, R.L.; Liebig, J.; Thürmann, L.; Corman, V.M.; Binder, M.; Loske, J.; Klasa, C.; et al. Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. Nat. Biotechnol. 2021, 39, 705–716. [Google Scholar] [CrossRef] [PubMed]
- Zhao, H.J.; Li, Y.; Wang, D.Y.; Yuan, H.T. ARB might be superior to ACEI for treatment of hypertensive COVID-19 patients. J. Cell. Mol. Med. 2021, 25, 11031–11034. [Google Scholar] [CrossRef] [PubMed]
- Luna, P.; Fernanda Pérez, M.; Castellar-Lopez, J.; Chang, A.; Montoya, Y.; Bustamante, J.; Rosales-Rada, W.; Mendoza-Torres, E. Potential of angiotensin-(1-7) in COVID-19 treatment. Curr. Protein Pept. Sci. 2023, 24, 89–97. [Google Scholar] [PubMed]
- Zhang, H.; Zang, C.; Xu, Z.; Zhang, Y.; Xu, J.; Bian, J.; Morozyuk, D.; Khullar, D.; Zhang, Y.; Nordvig, A.S.; et al. Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes. Nat. Med. 2023, 29, 226–235. [Google Scholar] [CrossRef]
- Mizrahi, B.; Sudry, T.; Flaks-Manov, N.; Yehezkelli, Y.; Kalkstein, N.; Akiva, P.; Ekka-Zohar, A.; David, S.S.; Lerner, U.; Bivas-Benita, M.; et al. Long covid outcomes at one year after mild SARS-CoV-2 infection: Nationwide cohort study. BMJ 2023, 380, e072529. [Google Scholar] [CrossRef]
- Molinaro, G.; Gervais, N.; Adam, A. Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment—An in vitro experimental approach. Stroke 2002, 33, 1712–1716. [Google Scholar] [CrossRef] [Green Version]
- Regoli, D.; Barabe, J. Pharmacology of bradykinin and related kinins. Pharm. Rev. 1980, 32, 1–38. [Google Scholar]
- Schreiber, U.; Engl, C.; Bayer, M.; König, S. Neuropeptide reporter assay for serum, capillary blood and blood cards. MethodsX 2020, 7, 100985. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
König, S.; Vollenberg, R.; Tepasse, P.-R. The Renin–Angiotensin System in COVID-19: Can Long COVID Be Predicted? Life 2023, 13, 1462. https://doi.org/10.3390/life13071462
König S, Vollenberg R, Tepasse P-R. The Renin–Angiotensin System in COVID-19: Can Long COVID Be Predicted? Life. 2023; 13(7):1462. https://doi.org/10.3390/life13071462
Chicago/Turabian StyleKönig, Simone, Richard Vollenberg, and Phil-Robin Tepasse. 2023. "The Renin–Angiotensin System in COVID-19: Can Long COVID Be Predicted?" Life 13, no. 7: 1462. https://doi.org/10.3390/life13071462